1. Search Result
Search Result
Results for "

neurodegenerative related diseases

" in MedChemExpress (MCE) Product Catalog:

64

Inhibitors & Agonists

8

Screening Libraries

1

Fluorescent Dye

8

Natural
Products

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N1100

    (-)-Vasicinone

    Others Neurological Disease
    Vasicinone is a quinazoline alkaloid isolated from the Adhatoda vasica. Vasicinone is a potential agent for Parkinson's disease and possibly other oxidative stress-related neurodegenerative disorders .
    Vasicinone
  • HY-147108

    Mitochondrial Metabolism Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Mitochondria degrader-1 (example 5) is a potent mitochondria degrader. Mitochondria degrader-1 induces the degradation of the injured mitochondria by the autophagy mechanism. Mitochondria degrader-1 can be used for the research of neurodegenerative disease, cancer, inflammatory disease, age-related disease, metabolic disease, mitochondrial disease or Down's disease .
    Mitochondria degrader-1
  • HY-142777

    Phospholipase Neurological Disease
    Lp-PLA2-IN-9 (compound 17), a tetracyclic pyrimidinone compound, is a potent Lp-PLA2 inhibitor with a pIC50 of 10.1 for rhLp-PLA2. Lp-PLA2-IN-9 has the potential for neurodegenerative related diseases research .
    Lp-PLA2-IN-9
  • HY-142774

    Phospholipase Neurological Disease
    Lp-PLA2-IN-6 (compound 18), a tetracyclic pyrimidinone compound, is a potent Lp-PLA2 inhibitor with a pIC50 of 10.0 for rhLp-PLA2. Lp-PLA2-IN-6 has the potential for neurodegenerative related diseases research .
    Lp-PLA2-IN-6
  • HY-160169

    Necroptosis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Necrosis inhibitor 2 (Compound B19) is a cell necrosis inhibitor. Necrosis inhibitor 2 can be used to study diseases related to the necrosis pathway, including inflammation, tumors, metabolic diseases and neurodegenerative diseases .
    Necrosis inhibitor 2
  • HY-158794

    Autophagy Neurological Disease
    Lentztrehalose B is a dehydroxylated analog of trehalose A, possessing antioxidant properties that can be used in research on neurodegenerative diseases and other autophagy-related conditions .
    Lentztrehalose B
  • HY-160169A

    Necroptosis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Necrosis inhibitor 2 hydrocholide (Compound B19) is a cell necrosis inhibitor. Necrosis inhibitor 2 hydrocholide can be used to study diseases related to the necrosis pathway, including inflammation, tumors, metabolic diseases and neurodegenerative diseases .
    Necrosis inhibitor 2 (hydrocholide)
  • HY-153183

    Phospholipase Cardiovascular Disease Neurological Disease
    Lp-PLA2-IN-12 (compound 19) is an Lp-PLA2 inhibitor. Lp-PLA2-IN-12 can be used for the study of neurodegenerative related diseases such as Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), or cardiovascular disease including atherosclerosis .
    Lp-PLA2-IN-12
  • HY-173366

    Molecular Glues Neurological Disease Cancer
    dGEM3 is a molecular glue degrader targeting GEMIN3 (a member of the survival of motor neuron complex). dGEM3 can be used in the research of diseases related to abnormal protein regulation, such as cancer and neurodegenerative diseases .
    dGEM3
  • HY-163175

    Cholinesterase (ChE) Neurological Disease
    BChE-IN-24 is a selective and reversible BChE inhibitor with an IC50 of 9 nM. BChE-IN-24 can be used for the research of Alzheimer’s disease and related neurodegenerative disorders .
    BChE-IN-24
  • HY-174991

    IRE1 Neurological Disease Cancer
    CPD-2828 is an orally active and selective IRE1α inhibitor with an IC50 value of 1.2 μM. CPD-2828 is promising for research of endoplasmic reticulum stress-related diseases (e.g., cancer, neurodegenerative diseases) .
    CPD-2828
  • HY-153560

    Phospholipase Neurological Disease
    Lp-PLA2-IN-14 (Compound 19) is an Lp-PLA2 inhibitor with a pIC50 of 8.4 against rhLp-PLA2. Lp-PLA2-IN-14 can be used for the research of neurodegenerative related diseases, such as Alzheimer Disease (AD), glaucoma, age-related macular degeneration (AMD) or cardiovascular diseases including atherosclerosis and the like .
    Lp-PLA2-IN-14
  • HY-174340

    Nuclear Hormone Receptor 4A/NR4A Neurological Disease
    Nurr1 agonist 13 (Compound 1) is a potent nuclear receptor related 1 (Nurr1, NR4A2) agonist with an EC50 value of 0.06 μM. Nurr1 agonist 13 is promising for research of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and multiple sclerosis .
    Nurr1 agonist 13
  • HY-G0017
    N-Desmethyl imatinib
    1 Publications Verification

    Norimatinib; Imatinib metabolite N-Desmethyl imatinib

    Drug Metabolite Cancer
    N-Desmethyl imatinib (Norimatinib) is a c-Abl tyrosine kinase inhibitor. N-Desmethyl imatinib binds to the c-Abl catalytic domain to prevent substrate phosphorylation, inhibits c-Abl-mediated α-synuclein activation and downstream inflammatory signaling pathways, and inhibits c-Abl-related neurodegenerative activity and neuroinflammation in vitro. N-Desmethyl imatinib can be used to study neurodegenerative diseases (such as Parkinson's disease) .
    N-Desmethyl imatinib
  • HY-153559

    Phospholipase Neurological Disease
    Lp-PLA2-IN-13 (compound 15) is a potent Lp-PLA2 inhibitor. Lp-PLA2-IN-13 has the potential for the research of neurodegenerative related diseases .
    Lp-PLA2-IN-13
  • HY-174157

    Autophagy AMPK Neurological Disease Metabolic Disease
    AR493 is an autophagy activator acting on AMPK (adenosine monophosphate-activated protein kinase). AR493 regulates pathways related to cellular energy sensing and increases autophagy levels. AR493 is promising for research of aging-associated diseases (such as diabetes, neurodegenerative diseases) and autophagy regulation .
    AR493
  • HY-W026109

    Fat Mass and Obesity-associated Protein (FTO) Neurological Disease
    FTO-IN-12 (Compound 2) is an inhibitor of fat mass and obesity-related protein (FTO). Kd and IC50 values are 185 nM and 1.46 μM, respectively. FTO-IN-12 can be used in the study of neurodegenerative diseases .
    FTO-IN-12
  • HY-N1100R

    (-)-Vasicinone (Standard)

    Reference Standards Others Neurological Disease
    Vasicinone (Standard) is the analytical standard of Vasicinone. This product is intended for research and analytical applications. Vasicinone is a quinazoline alkaloid isolated from the Adhatoda vasica. Vasicinone is a potential agent for Parkinson's disease and possibly other oxidative stress-related neurodegenerative disorders .
    Vasicinone (Standard)
  • HY-161911

    Necroptosis RIP kinase Neurological Disease Inflammation/Immunology Cancer
    Necroptosis-IN-5 (Compound 26) is an orally active necroptosis inhibitor. Necroptosis-IN-5 also exhibits potent inhibitory activity against receptor-interacting protein kinase 1 (RIPK1). Necroptosis-IN-5 can be used to study necroptosis-related inflammatory diseases, neurodegenerative diseases, and cancers .
    Necroptosis-IN-5
  • HY-142936

    ROR Neurological Disease Inflammation/Immunology Cancer
    RORγt modulator 3 (Compound 23) is a modulator of retinoid-related orphan receptor γt (RORγt). RORγt modulator 3 can be used for the research of RORyt mediated diseases such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer .
    RORγt modulator 3
  • HY-W181102

    Calcineurin Cardiovascular Disease Neurological Disease Inflammation/Immunology
    NFAT Inhibitor-2 is a potent inhibitor of calcineurin NFAT signalling. Calcineurin is a serine/threonine protein phosphatase regulated by Ca2+ and calmodulin. NFAT Inhibitor-2 has the potential for the research of inflammatory disease, an autoimmune disorder, a cardiovascular disease, a neurodegenerative disease, a disease occurring with uncontrolled cell proliferation and/or differentiation, an angiogenesis-related disease, an allergy, anaphylaxis and alopecia (extracted from patent WO2016207212A1, compound 17) .
    NFAT Inhibitor-2
  • HY-142935

    ROR Neurological Disease Inflammation/Immunology Cancer
    RORγt modulator 2 (Compound 21) is a modulator of retinoid-related orphan receptor γt (RORγt) with the IC50 of <50 nM. RORγt modulator 2 can be used for the research of RORyt mediated diseases such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer .
    RORγt modulator 2
  • HY-147564

    RET Neurological Disease Cancer
    RET-IN-18 is a pyridone compound. is a potent inhibitor of RET. RET-IN-18 is a potent inhibitor of RET. RET-IN-18 has the potential for the research of diseases related to irritable bowel syndrome (IBS) and other gastrointestinal disorders, as well as cancers, and neurodegenerative diseases (extracted from patent WO2022017524A1, compound 1) .
    RET-IN-18
  • HY-N7607

    Reactive Oxygen Species (ROS) Cardiovascular Disease
    Quercetin-3-O-D-glucosyl]-(1-2)-L-rhamnoside is a flavonoid glycoside with antioxidant activity and free radical scavenging activity. Quercetin-3-O-D-glucosyl]-(1-2)-L-rhamnoside can scavenge free radicals such as ABTS+ and can be used in the study of antioxidant-related diseases (such as cardiovascular diseases and neurodegenerative diseases) .
    Quercetin-3-O-D-glucosyl]-(1-2)-L-rhamnoside
  • HY-148322

    Sirtuin Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Sirtuin modulator 5 is a sirtuin modulating agent. Sirtuin modulator 5 can activate SIRT1 with a DC50 value of <50 μM. Sirtuin modulator 5 can be used for increasing the lifespan of a cell and used for the research of variety of diseases including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity .
    Sirtuin modulator 5
  • HY-173509

    Phosphodiesterase (PDE) LPL Receptor Infection Cardiovascular Disease Neurological Disease Cancer
    ATX inhibitor 27 (Compound 31) is an ATX inhibitor. The IC50 values of ATX inhibitor 27 against human autotaxin (hATX) and lysophosphatidylcholine (LPC) are 13 nM and 23 nM, respectively. ATX inhibitor 27 reduces LPA levels in vivo by inhibiting ATX enzyme. ATX inhibitor 27 can be used in the study of ATX-LPA-related diseases such as inflammation, neurodegenerative diseases and cancer .
    ATX inhibitor 27
  • HY-174335

    Cannabinoid Receptor Neurological Disease
    UVI3502 is a cannabinoid receptor 1 (CB1) antagonist with an IC50 value of 4641 nM for CB1 and approximately 16200 nM for CB2. UVI3502 blocks Gi/o protein coupling induced by the agonist CP55,940. UVI3502 is promising for research of endocannabinoid system-related diseases in the central nervous system (such as cognitive impairment and neurodegenerative diseases) .
    UVI3502
  • HY-113155A

    Drug Intermediate Neurological Disease
    17-Hydroxypregnenolone sulfate sodium is a key brain-penetrant intermediate in adrenal and gonadal steroidogenesis. 17-Hydroxypregnenolone sulfate sodium acts as a precursor in the biosynthesis of steroid hormones (e.g., glucocorticoids, sex hormones). 17-Hydroxypregnenolone sulfate sodium is promising for research of adrenal function development and neurosteroid-related diseases (e.g., cognitive impairment, neurodegenerative diseases) .
    17-Hydroxypregnenolone sulfate sodium
  • HY-139331

    Proteasome Neurological Disease Inflammation/Immunology Cancer
    20S Proteasome-IN-1 is a 26S proteasome inhibitor extracted from patent WO2006128196A2 compound 2. 20S Proteasome-IN-1 has the potential for cancer, immune-related disorders, inflammation, ischemic conditions, neurodegenerative disorders and other diseases research .
    20S Proteasome-IN-1
  • HY-142778

    Phospholipase Neurological Disease Metabolic Disease
    Lp-PLA2-IN-10 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-10 has the potential for the research of neurodegenerative-related diseases such as Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), or cardiovascular diseases including atherosclerosis (extracted from patent WO2022001881A1, compound 4) .
    Lp-PLA2-IN-10
  • HY-W319939

    Lipoxygenase Cardiovascular Disease Neurological Disease
    3-(4-Hydroxy-3-methoxyphenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one (Compound 5) is a selective lipid peroxidation inhibitor. 3-(4-Hydroxy-3-methoxyphenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one is promising for research of diseases related to oxidative stress, such as cardiovascular diseases and neurodegenerative diseases .
    3-(4-Hydroxy-3-methoxyphenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one
  • HY-174834

    Monoamine Oxidase Neurological Disease
    MAO-B-IN-44 (Compound 4n) is a selective monoamine oxidase B (MAO-B) inhibitor targetin with an IC50 value of 1.01 μM, showing weak inhibition on MAO-A (IC50=14.4 μM). MAO-B-IN-44 reduces degradation of neurotransmitters like dopamine. MAO-B-IN-44 is promising for research of neurodegenerative diseases related to MAO-B abnormalities such as Parkinson’s disease .
    MAO-B-IN-44
  • HY-169555

    ASK1 Cardiovascular Disease Neurological Disease Inflammation/Immunology
    ASK1-IN-7 (Compound 4c) is an ASK1 inhibitor and a derivative of the ASK1 inhibitor scaffold 5-(5-Phenyl-furan-2-ylmethylene)-2-thioxo-thiazolidin-4-one. ASK1-IN-7 holds promise for research related to the ASK1 signaling pathway, such as cell stress responses, inflammation, neurodegenerative diseases, and cardiovascular diseases .
    ASK1-IN-7
  • HY-14562

    mAChR Amyloid-β Neurological Disease Inflammation/Immunology
    TBPB (tert-butyl peroxybenzoate) is a highly selective, blood-brain-permeable M1 mAChR allosteric agonist (EC50=289 nM) with anti-schizophrenia and anti-inflammatory activities. TBPB can enhance the sensitivity of M1 receptors to acetylcholine, activate downstream signaling pathways, and inhibit the release of pro-inflammatory cytokines (TNF-α, IL-6). TBPB can regulate the processing of amyloid and can be used in the study of neurodegenerative diseases (such as Alzheimer's disease) and inflammation-related diseases (such as sepsis) .
    TBPB
  • HY-173276

    Toll-like Receptor (TLR) Neurological Disease
    SARM1-IN-4 (Compound 7) is an orally active SARM1 inhibitor. After being orally administered at a dose of 50 mg/kg in a mouse model, it can reduce the level of plasma neurofilament light chain (NfL). SARM1-IN-4 prevents programmed axonal degeneration by inhibiting the NAD+ hydrolase activity of SARM1, and it can be used in research related to neurodegenerative diseases and neurological disorders (such as multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease, and peripheral neuropathies, etc.).
    SARM1-IN-4
  • HY-174329

    Molecular Glues Neurological Disease Cancer
    mrt-5702D is a molecular glue degrader targeting cereblon (CRBN). mrt-5702D forms a CRBN-MRT-5702D-G3BP2 ternary complex to activate the ubiquitin-proteasome system for G3BP2 degradation. mrt-5702D is promising for research of G3BP2-related cancers (e.g., breast cancer, lung cancer) and neurodegenerative diseases .
    mrt-5702D
  • HY-169330

    Drug Metabolite Neurological Disease Metabolic Disease
    3β,5α,6β-Trihydroxycholanic acid is a metabolite of 3β,5α,6β-Trihydroxycholestane (HY-W010934). 3β,5α,6β-Trihydroxycholanic acid can be used in research related to neurodegenerative diseases associated with lysosomal dysfunction .
    3β,5α,6β-Trihydroxycholanic acid
  • HY-137441
    Icapamespib
    1 Publications Verification

    PU-HZ151

    HSP Neurological Disease Cancer
    Icapamespib (PU-HZ151; PU-AD) is a selective, orally active inhibitor of Epichaperomes assembled by HSP90 with slow dissociation kinetics. Icapamespib can cross the blood-brain barrier (BBB) ??and induce epichaperome disassembly by non-covalently binding to HSP90, restoring the normal protein-protein interaction network. Icapamespib can specifically disrupt disease-related abnormal protein interaction networks, reduce neurotoxic protein aggregation and tumor cell survival signals. Icapamespib can be used in the research of neurodegenerative diseases such as Alzheimer's disease, as well as cancers such as glioblastoma and metastatic breast cancer .
    Icapamespib
  • HY-137441A
    Icapamespib hydrochloride
    1 Publications Verification

    PU-HZ151 hydrochloride

    HSP Neurological Disease Cancer
    Icapamespib (PU-HZ151; PU-AD) hydrochloride is a selective, orally active inhibitor of Epichaperomes assembled by HSP90 with slow dissociation kinetics. Icapamespib hydrochloride can cross the blood-brain barrier (BBB) ??and induce epichaperome disassembly by non-covalently binding to HSP90, restoring the normal protein-protein interaction network. Icapamespib hydrochloride can specifically disrupt disease-related abnormal protein interaction networks, reduce neurotoxic protein aggregation and tumor cell survival signals. Icapamespib hydrochloride can be used in the research of neurodegenerative diseases such as Alzheimer's disease, as well as cancers such as glioblastoma and metastatic breast cancer .
    Icapamespib hydrochloride
  • HY-111093

    CaMK Neurological Disease
    Protein kinase inhibitor 8 (Compound CK59) is a calmodulin-dependent protein kinase II (CaMKII) inhibitor. By inhibiting the activity of CaMKII, Protein kinase inhibitor 8 can attenuate the cytotoxicity induced by perfluorooctane sulfonic acid (PFOS) and alleviate the downregulation of GLT-1 expression caused by PFOS, thereby reducing neuronal damage. Protein kinase inhibitor 8 may be useful in research related to neurodegenerative diseases .
    Protein kinase inhibitor 8
  • HY-117403

    Cannabinoid Receptor Potassium Channel
    AB-FUBICA (Compound 13) is a CB1 and CB2 receptor agonist that activates G-protein coupled inwardly rectifying potassium channels (GIRK) by binding to CB1 and CB2 receptors, displaying notable cannabinoid-like activity. AB-FUBICA has EC50 values of 21 nM for CB1 and 15 nM for CB2. AB-FUBICA may be suitable for studying pain management, neurodegenerative diseases, and inflammation-related mechanisms .
    AB-FUBICA
  • HY-145232
    PhosTAC7
    3 Publications Verification

    Phosphatase Tau Protein Neurological Disease Cancer
    PhosTAC7 is a heterobifunctional molecule named as a Phosphorylation Targeting Chimera (PhosTAC). PhosTAC7 can dephosphorylate the PDCD4 protein, FOXO3a protein, and Tau protein by recruiting serine/threonine protein phosphatase 2A (PP2A). PhosTAC7 offers the advantage of selectively modulating the phosphorylation state of individual target proteins, making it a promising tool for research in cancer and tau protein-related neurodegenerative diseases .
    PhosTAC7
  • HY-147225

    AUTACs Mitophagy Neurological Disease Metabolic Disease Cancer
    TSPO Ligand-Linker Conjugates 1 contains a ligand for translocator protein (TSPO) and a linker, which is used for the synthesis of mitochondria-targeting autophagy-targeting chimera (AUTAC). AUTAC can bind the TSPO on the outer mitochondrial membrane (OMM) of mitochondria and degrades impaired mitochondria and proteins via mitophagy, and improves mitochondrial activity. TSPO Ligand-Linker Conjugates 1 can be used in mitochondrial dysfunction related research, including neurodegenerative diseases, cancer, and diabetes .
    TSPO Ligand-Linker Conjugates 1
  • HY-W338446

    Tau Protein Neurological Disease
    BF-170 is a selective tau fibril binding agent with an EC50 of 221 nM. It exhibits good blood-brain barrier permeability, and after intravenous injection in mice, the concentration in brain tissue reaches 9.1% ID/g within 2 minutes (with a brain clearance rate of 0.25% ID/g after 30 minutes). BF-170 can be used as a probe for tau protein pathology imaging in Alzheimer's disease (AD). It plays an important role in early-stage AD research and holds potential for imaging studies of tau-related neurodegenerative diseases .
    BF-170
  • HY-114727

    Phosphodiesterase (PDE) Inflammation/Immunology
    PDE7-IN-4 is a phosphodiesterase 7 (PDE7) inhibitor with activity that increases intracellular cyclic adenosine monophosphate (cAMP) levels. PDE7-IN-4 shows potential inhibitory effects in neurotransmission and anti-inflammatory applications. PDE7-IN-4 exerts its biological activity by acting on the cAMP/cAMP response element binding protein (CREB) pathway. The development of PDE7-IN-4 aims to improve its pharmacokinetic characteristics to more effectively target neurodegenerative diseases and other inflammation-related diseases .
    PDE7-IN-4
  • HY-115733
    Cathepsin L-IN-2
    1 Publications Verification

    (Rac)-Z-Phe-Phe-FMK

    Cathepsin Cancer
    Cathepsin L-IN-2 ((Rac)-Z-Phe-Phe-FMK) is an isomer of the Cathepsin L inhibitor Z-Phe-Phe-FMK (HY-141867), with an IC50 of 15 μM for cathepsin L. Z-Phe-Phe-FMK irreversibly blocks the proteolytic function of cathepsins by covalently binding to the cysteine residues in the active center of the enzyme. Cathepsin L-IN-2 and Z-Phe-Phe-FMK can be used to study neurodegenerative diseases (such as GRN-related frontotemporal dementia) and cancer invasion and metastasis.
    Cathepsin L-IN-2
  • HY-111914A

    NO Synthase Fatty Acid Synthase (FASN) Cardiovascular Disease
    Ferroheme is the ferrous form of heme in hemoglobin, reversibly binding oxygen as an oxygen carrier. Its free form induces oxidative stress and ferroptosis by releasing iron ions, which catalyze reactive oxygen species generation via Fenton reactions, leading to lipid peroxidation and cell death. This mechanism is critical in pathological contexts like intracerebral hemorrhage and neurodegenerative diseases, making it a target for studying iron-overload disorders and ferroptosis-related pathologies[1][2][3].
    Ferroheme
  • HY-113324
    NADPH
    Maximum Cited Publications
    11 Publications Verification

    Endogenous Metabolite Cancer
    NADPH is a coenzyme of glutathione reductase (GR), thioredoxin reductase (TrxR) and NADPH oxidase (NOX), and participates in redox reactions as a hydrogen donor. NADPH has the characteristic of selectively participating in the regulation of cellular redox homeostasis. NADPH exerts antioxidant activity and resists reactive oxygen species (ROS) damage by providing reducing equivalents for the regeneration of glutathione (GSH) and thioredoxin (Trx); at the same time, it acts as a substrate of NOX to generate superoxide anions, mediating oxidative stress and immune response. NADPH participates in maintaining the intracellular reducing environment, biosynthesis and regulating gene expression (such as the Nrf2 pathway), and is mainly used in the study of oxidative stress-related diseases (such as cardiovascular diseases, neurodegenerative diseases, cancer) and immune regulation mechanisms .
    NADPH
  • HY-113218
    Acetyl-L-carnitine
    2 Publications Verification

    O-Acetyl-L-carnitine; ALCAR

    Caspase Apoptosis Neurological Disease
    Acetyl-L-carnitine (O-Acetyl-L-carnitine; ALCAR) is an orally active mitochondrial energy metabolism regulator and neuroprotectant that can penetrate the blood-brain barrier. Acetyl-L-carnitine selectively enters cells and the brain through the organic cation transporter OCTN2. Acetyl-L-carnitine can participate in fatty acid β-oxidation, promote acetylcholine synthesis, regulate mitochondrial function and inhibit oxidative stress as an acetyl donor. Acetyl-L-carnitine exerts its activity by enhancing energy metabolism, protecting neurons and improving synaptic plasticity. Acetyl-L-carnitine is mainly used in the study of neurodegenerative diseases and metabolic disorder-related diseases such as neonatal hypoxic-ischemic brain damage, Alzheimer's disease, and depression .
    Acetyl-L-carnitine
  • HY-B0762
    Acetyl-L-carnitine hydrochloride
    2 Publications Verification

    O-Acetyl-L-carnitine hydrochloride; ALCAR hydrochloride

    Caspase Apoptosis Neurological Disease
    Acetyl-L-carnitine (O-Acetyl-L-carnitine; ALCAR) hydrochloride is an orally active mitochondrial energy metabolism regulator and neuroprotectant that can penetrate the blood-brain barrier. Acetyl-L-carnitine hydrochloride selectively enters cells and the brain through the organic cation transporter OCTN2. Acetyl-L-carnitine hydrochloride can participate in fatty acid β-oxidation, promote acetylcholine synthesis, regulate mitochondrial function and inhibit oxidative stress as an acetyl donor. Acetyl-L-carnitine hydrochloride exerts its activity by enhancing energy metabolism, protecting neurons and improving synaptic plasticity. Acetyl-L-carnitine hydrochloride is mainly used in the study of neurodegenerative diseases and metabolic disorder-related diseases such as neonatal hypoxic-ischemic brain damage, Alzheimer's disease, and depression .
    Acetyl-L-carnitine hydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: